Species specific immunoassays to measure blood platelet and coagulation activation in the rat

Thrombosis and Haemostasis

Volumn 76, Issue 6, 1996, Pages 1090-1095

  Ravanat, C ^a   Freund, M ^a,b   Schuhler, S ^a   Grunert, P ^a   Meyer, L ^b   Cazenave, J P ^a  

^a INSERM   (France)

^b Laboratoire Centeon   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; FIBRINOGEN; FIBRINOPEPTIDE A; HIRUDIN; THROMBIN; THROMBOCYTE FACTOR 4; THROMBOPLASTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FIBRINOGEN BLOOD LEVEL; HYPERCOAGULABILITY; IMMUNOASSAY; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT;

EID: 0030443157     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650711     Document Type: Article

References (38)

1. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-50.
2. Mannucci PM, Giangrande PLF. Detection of the prethrombotic state due to procoagulant imbalance. Eur J Haematol 1992; 48: 65-9.
3. Boisclair MD, Philippou H, Lane DA. Thrombogenic mechanisms in the human: fresh insights obtained by immunodiagnostic studies of coagulation markers. Blood Coag Fibrinol 1993; 4: 1007-21.
4. Nossel HL, Yudelman I, Canfield RE, Butler VP, Spanondis K, Winer GD, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-53.
5. Amiral J, Walenga JM, Fareed J. Development and performance characteristics of a competitive enzyme immunoassay for fibrinopeptide A. Semin Thromb Haemost 1984; 10: 228-42.
6. Lau HK, Rosenberg JS, Beeler DL, Rosenberg RD. The isolation and characterization of a specific antibody population directed against the prothrombin activation fragment F2 and F 1+2. J Biol Chem 1979; 254: 8751-61.
7. Pelzer H, Schwarz A, Heimburger N. Determination of human thrombinantithrombin III complex in plasma with enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101-6.
8. Files JC, Malpass TW, Yee EK, Ritchie JL, Harker LA. Studies of human platelet α-granule release in vivo. Blood 1981; 58: 607-18.
9. Kaplan KL, Owen J. Plasma levels of β-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1988; 57: 199-202.
10. Amiral J, Adam M, Mimilla F, Larrivaz I, Chambrette B, Boffa MC. Design and validation of a new immunoassay for soluble forms of thrombomodulin and studies on plasma. Hybridoma 1994; 13: 205-13.
11. Bounameaux H, de Moerloose P, Perrier A, Reber G. Plasma measurement of D-dimers as diagnostic aid in suspected venous thromboembolism: an overview. Thromb Haemost 1994; 71: 1-6.
12. Ravanat C, Freund M, Herbert JM, Dol F, Maffrand JP, Boneu B, Cadroy Y, Drouet L, Roussi J, Legrand C, Incardona F, Cazenave JP. Cross-reactivity of human molecular markers for detection of prethrombotic states in various animal species. Blood Coag Fibrinol 1995; 6: 446-55.
13. Shigeta O, Lu W, Holt JC, Edmunds LH, Niewiarowski S. Ovine platelet factor 4 : purification, amino acid sequence, radioimmunoassay and comparison with platelet factor 4 of other species. Thromb Res 1991; 64: 509-20.
14. Uchiyama H, Ohtani H, Hiraishi S, Horie S, Ishii H, Kazawa M. Changes in plasma thrombomodulin antigen in rabbit developing endotoxin-induced disseminated intravascular coagulation and the effect of heparin. Thromb Res 1992; 65: 593-604.
15. Fredrich M, Zierz R, Morser J, Wydro R, Witt W. A new animal model of venous thrombosis in rats with low flow conditions in the venous blood stream. Blood Coag Fibrinol 1994; 5: 243-8.
16. Drummond O, McLaughlin LF, MacGregor IR. Development of a radioimmunoassay for rat fibrinopeptide A. Br J Haematol 1991; 77: 59.
17. Chen JP, Marsh LC, Schroeder EC. Haemostatic derangements associated with arenavirus infection in the guinea-pig: radioimmunoassay of fibrinopeptide A to assess thrombin action in infected animals. Blood Coag Fibrinol 1993, 4: 165-72.
18. MacGregor IR, Ferguson JF, Dawes J, McLaughlin L., Prowse CV. Thrombogenicity of a factor IX concentrate quantitated in a canine model. Blood Coag Fibrinol 1990; 1: 23-30.
19. Spannagl M, Trauner A, Birg A, Frank G, Hoffmann H, Siebeck M, Lill H. Sensitive detection of the activation state of blood coagulation in porcine DIC models by a new fibrin immunoassay. Blood Coag Fibrinol 1993; 4: 103-6.
20. Winocour PD, Chignier E, Parmentier S, McGregor JL. A member of the selectin family (GMP-140/PADGEM) is expressed on thrombin-stimulated rat platelets in vitro. Comp Biochem Physiol 1992; 102A: 265-71.
21. Chignier E, Parise M, McGregor L, Delabre C, Faucomprel S, McGregor J. A P-selectin/CD62P monoclonal antibody (LYP-20), in tandem with flow cylometry, detects in vivo activated circulating rat platelets in severe vascular trauma. Thromb Haemost 1994; 72: 745-8.
22. Ravanat C, Schuhler S, Morales M, Cazenave JP, Lanza F. Cloning of the gene for rat platelet GPV, purification of the protein and development of an anti-peptide antibody for the detection of rat thrombin-activated platelets. Thromb Haemost 1995; 73: 1196.
23. Nawa K, Itani T, Ono M, Sakano K, Marumoto Y, Iwamoto M. The glycosaminoglycan of recombinant human soluble thrombomodulin affects antithrombotic activity in a rat model of tissue factor-induced disseminated intravascular coagulation. Thromb Haemost 1992; 67: 366-70.
24. Dickneite G, Czech J, Keuper H. Formation of fibrin monomers in experimental disseminated intravascular coagulation and its inhibition by recombinant hirudin. Circ Shock 1994; 42: 183-9.
25. Markwardt F. Hirudin as an inhibitor of thrombin. In: Methods in enzymology. Vol. 29. Academic Press. New York 1970; pp 924-32.
26. Ravanat C, Gachet C, Herbert JM, Schuhler S, Guillemot JC, Uzabiaga F, Picard C, Ferrara P, Freund M, Cazenave JP. Rat platelets contain glycosylated and non glycosylated forms of platelet factor 4. Identification and characterization by mass spectrometry. Eur J Biochem 1994; 223: 203-10.
27. McKinney MM, Parkinson A. A simple, non-chromatographic procedure to purify immunoglobulins from serum and ascites fluid. J Immunol Methods 1987; 96: 271-8.
28. Weiss HJ, Witte LD, Kaplan KL, Lages BA, Chernoff A, Nossel HL, Goodman DS, Baumgartner HR. Heterogeneity in storage pool deficiency: Studies on α-granule-bound substances in 18 patients including variants deficient in α-granules, platelet factor 4, β-thromboglobulin, and platelet-derived growth factor. Blood 1979; 54: 1296-319.
29. Carson SD, Brozna JP. The role of tissue factor in the production of thrombin. Blood Coag Fibrinol 1993; 4: 281-92.
30. MacGregor IR, McLaughlin LF, Drummond O, Prowse CV, Ferguson JM. In vivo models of thrombogenic potential: usefulness and limitations. Acta Haematol 1995; 94: 18-24.
31. Freund M, Cazenave JP, Courtney M, Degryse E, Roitsch C, Bernart A, Delebassé D, Defreyn G, Maffrand JP. Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats. Thromb Haemost 1990; 63: 187-92.
32. Freund M, Mantz F, Nicolini P, Gachet C, Mulvihill J, Meyer L, Beretz A, Cazenave JP. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition. Thromb Haemost 1993; 69: 515-21.
33. Herbert JM, Bernart A, Maffrand JP. Importance of platelets in experimental venous thrombosis in rat. Blood 1992; 80: 2281-6.
34. Dickneite G, Pâques EP. Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae induced sepsis. Thromb Haemost; 1993; 69: 98-102.
35. Ivanov VS, Suvorova ZK, Tchikin LD, Kozhich AT, Ivanov VT. Effective method for synthetic peptide immobilization that increases the sensitivity and specificity of ELISA procedures. J Immunol Methods 1992; 153: 229-33.
36. McLaughlin LF, Drummond O, MacGregor IR. A novel rat model of thrombogenicity: its use in evaluation of prothrombin complex concentrates and high purity Factor IX concentrates. Thromb Haemost 1992; 68: 511-5.
37. Cella G, Myers CJ, Prosdocimi M, Sasahara AA. Human platelet factor 4 and protamine sulphate interaction with glycosaminoglycan in the rabbit. Eur J Clin Invest 1987; 17: 548-54.
38. Weiss HJ, Witte LD, Kaplan KL, Lages BA, Chernoff A, Nossel HL, Goodman DS, Baumgartner HR. Heterogeneity in storage pool deficiency: Studies on granule-bound substances in 18 patients including variants deficient in α-granules, platelet factor 4, β-thromboglobulin, and platelet-derived growth factor. Blood 1979; 54: 1296-319.